0
BMY
BRISTOL-MYERS SQUIBB CO · Health Care
Consensus score 0/100 · #303 this quarter · tier-weighted across tracked managers
→NeutralPrice action since filingas of 2026-06-05
vs 50-day avg
-1.3%
21-day momentum
+1.2%
recent volume
1.17×
13F filings lag ~45 days; this is current price/volume action on top — a technical read, not a prediction.
S2· AdvancingStage Analysis · Weinstein
vs 30-wk avg
+2.6%
30-wk MA slope
+3.3%
rel. strength
-0.2
52-wk range
72%
Advancing — above a rising 30-week trend with positive relative strength. Weinstein’s buy zone. Based on the 30-week (150-day) moving average + slope, Mansfield relative strength vs SPY, and volume. Technical read, not advice.
Holders
2
tracked managers
New this Q
0
opened a position
Avg weight
0.1%
of their portfolios
Combined value
$4M
held, at quarter-end
Who’s holding it Q1 2026, by position size
| Manager | Position size | Value | Change |
|---|---|---|---|
| Tweedy Browne Graham/global value | 0.1% | $2M | ADD |
| Horizon Kinetics Franchise/inflation | 0.0% | $3M | TRIM |
Position size = share of that manager’s reported long US-equity portfolio. The consensus score weights each holder by quality tier, position size, and whether they were buying or trimming — then discounts very crowded names. It measures agreement among these managers, not expected return.